Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2024

Open Access 01-12-2024 | Research

Association of plasma proteomics with incident coronary heart disease in individuals with and without type 2 diabetes: results from the population-based KORA study

Authors: Hong Luo, Marie-Theres Huemer, Agnese Petrera, Stefanie M. Hauck, Wolfgang Rathmann, Christian Herder, Wolfgang Koenig, Annika Hoyer, Annette Peters, Barbara Thorand

Published in: Cardiovascular Diabetology | Issue 1/2024

Login to get access

Abstract

Background

Coronary heart disease (CHD) is a major global health concern, especially among individuals with type 2 diabetes (T2D). Given the crucial role of proteins in various biological processes, this study aimed to elucidate the aetiological role and predictive performance of protein biomarkers on incident CHD in individuals with and without T2D.

Methods

The discovery cohort included 1492 participants from the Cooperative Health Research in the Region of Augsburg (KORA) S4 study with 147 incident CHD cases (45 vs. 102 cases in the group with T2D and without T2D, respectively) during 15.6 years of follow-up. The validation cohort included 888 participants from the KORA-Age1 study with 70 incident CHD cases (19 vs. 51 cases in the group with T2D and without T2D, respectively) during 6.9 years of follow-up. We measured 233 plasma proteins related to cardiovascular disease and inflammation using proximity extension assay technology. Associations of proteins with incident CHD were assessed using Cox regression and Mendelian randomization (MR) analysis. Predictive models were developed using priority-Lasso and were evaluated on top of Framingham risk score variables using the C-index, category-free net reclassification index (cfNRI), and relative integrated discrimination improvement (IDI).

Results

We identified two proteins associated with incident CHD in individuals with and 29 in those without baseline T2D, respectively. Six of these proteins are novel candidates for incident CHD. MR suggested a potential causal role for hepatocyte growth factor in CHD development. The developed four-protein-enriched model for individuals with baseline T2D (ΔC-index: 0.017; cfNRI: 0.253; IDI: 0.051) and the 12-protein-enriched model for individuals without baseline T2D (ΔC-index: 0.054; cfNRI: 0.462; IDI: 0.024) consistently improved CHD prediction in the discovery cohort, while in the validation cohort, significant improvements were only observed for selected performance measures (with T2D: cfNRI: 0.633; without T2D: ΔC-index: 0.038; cfNRI: 0.465).

Conclusions

This study identified novel protein biomarkers associated with incident CHD in individuals with and without T2D and reaffirmed previously reported protein candidates. These findings enhance our understanding of CHD pathophysiology and provide potential targets for prevention and treatment.
Appendix
Available only for authorised users
Literature
1.
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337.PubMedCrossRef
2.
Sattar N, Rawshani A, Franzen S, Rawshani A, Svensson AM, et al. Age at diagnosis of type 2 diabetes Mellitus and associations with Cardiovascular and Mortality risks. Circulation. 2019;139(19):2228–37.PubMedCrossRef
3.
Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. Br Med J (Clin Res Ed). 1983;287(6396):867–70.PubMedCrossRef
4.
Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. BMJ. 1989;299(6708):1127–31.PubMedPubMedCentralCrossRef
5.
Wik L, Nordberg N, Broberg J, Bjorkesten J, Assarsson E, et al. Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis. Mol Cell Proteomics. 2021;20:100168.PubMedPubMedCentralCrossRef
6.
Lind L, Arnlov J, Sundstrom J. Plasma protein Profile of Incident Myocardial Infarction, ischemic stroke, and Heart failure in 2 cohorts. J Am Heart Assoc. 2021;10(12):e017900.PubMedPubMedCentralCrossRef
7.
Molvin J, Jujic A, Melander O, Pareek M, Rastam L, et al. Proteomic exploration of common pathophysiological pathways in diabetes and cardiovascular disease. ESC Heart Fail. 2020;7(6):4151–8.PubMedPubMedCentralCrossRef
8.
Ong KL, Chung RWS, Hui N, Festin K, Lundberg AK, et al. Usefulness of certain protein biomarkers for prediction of Coronary Heart Disease. Am J Cardiol. 2020;125(4):542–8.PubMedCrossRef
9.
Lind L, Gigante B, Borne Y, Malarstig A, Sundstrom J, et al. The plasma protein profile and cardiovascular risk differ between intima-media thickness of the common carotid artery and the bulb: a meta-analysis and a longitudinal evaluation. Atherosclerosis. 2020;295:25–30.PubMedCrossRef
10.
Ferreira JP, Sharma A, Mehta C, Bakris G, Rossignol P, et al. Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial. Clin Res Cardiol. 2021;110(7):1006–19.PubMedCrossRef
11.
Goff DC Jr., Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. Circulation. 2014;129(25 Suppl 2):49–73.
12.
Beijer K, Nowak C, Sundstrom J, Arnlov J, Fall T, et al. In search of causal pathways in diabetes: a study using proteomics and genotyping data from a cross-sectional study. Diabetologia. 2019;62(11):1998–2006.PubMedPubMedCentralCrossRef
13.
14.
Gudmundsdottir V, Zaghlool SB, Emilsson V, Aspelund T, Ilkov M, et al. Circulating protein signatures and causal candidates for type 2 diabetes. Diabetes. 2020;69(8):1843–53.PubMedPubMedCentralCrossRef
15.
Ferreira JP, Pizard A, Machu JL, Bresso E, Rocca HB, et al. Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case-control analyses. Clin Res Cardiol. 2020;109(1):22–33.PubMedCrossRef
16.
Luo H, Bauer A, Nano J, Petrera A, Rathmann W, et al. Associations of plasma proteomics with type 2 diabetes and related traits: results from the longitudinal KORA S4/F4/FF4 study. Diabetologia. 2023;66(9):1655–68.PubMedCrossRef
17.
D’Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–53.PubMedCrossRef
18.
Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia. 2003;46(2):182–9.PubMedCrossRef
19.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53.PubMedCrossRef
20.
Peters A, Doring A, Ladwig KH, Meisinger C, Linkohr B, et al. Multimorbidity and successful aging: the population-based KORA-Age study. Z Gerontol Geriatr. 2011;44(Suppl 2):41–54.PubMedCrossRef
21.
Petrera A, von Toerne C, Behler J, Huth C, Thorand B, et al. Multiplatform Approach for plasma proteomics: complementarity of Olink Proximity Extension Assay Technology to Mass Spectrometry-based protein profiling. J Proteome Res. 2021;20(1):751–62.PubMedCrossRef
22.
Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, et al. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90(1):583–612.PubMedCrossRef
23.
Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined–a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36(3):959–69.PubMedCrossRef
24.
Lowel H, Lewis M, Hormann A, Keil U. Case finding, data quality aspects and comparability of myocardial infarction registers: results of a south German register study. J Clin Epidemiol. 1991;44(3):249–60.PubMedCrossRef
25.
Meisinger C, Thorand B, Schneider A, Stieber J, Doring A, et al. Sex differences in risk factors for incident type 2 diabetes mellitus: the MONICA Augsburg cohort study. Arch Intern Med. 2002;162(1):82–9.PubMedCrossRef
26.
World Health Organization, Part III, population survey: section 1, population survey data component: procedures for responders—blood pressure measurement. WHO MONICA Project: MONICA Manual. World Health Organization, Geneva, Switzerland; 1990. p.12–14.
27.
Sun BB, Chiou J, Traylor M, Benner C, Hsu YH, et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature. 2023;622(7982):329–38.PubMedPubMedCentralCrossRef
28.
Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, et al. Computationally efficient whole-genome regression for quantitative and binary traits. Nat Genet. 2021;53(7):1097–103.PubMedCrossRef
29.
30.
Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–25.PubMedPubMedCentralCrossRef
31.
Fabregat A, Sidiropoulos K, Garapati P, Gillespie M, Hausmann K, et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 2016;44(D1):D481–487.PubMedCrossRef
32.
Klau S, Jurinovic V, Hornung R, Herold T, Boulesteix AL. Priority-Lasso: a simple hierarchical approach to the prediction of clinical outcome using multi-omics data. BMC Bioinformatics. 2018;19(1):322.PubMedPubMedCentralCrossRef
33.
Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247(18):2543–6.PubMedCrossRef
34.
Pencina MJ, D’Agostino RB, Sr., Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(1):11–21.MathSciNetPubMedCrossRef
35.
Pencina MJ, D’Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med. 2010;48(12):1703–11.PubMedPubMedCentralCrossRef
36.
Kolossvary M, deFilippi C, Lu MT, Zanni MV, Fulda ES, et al. Proteomic signature of subclinical coronary artery disease in people with HIV: analysis of the REPRIEVE mechanistic substudy. J Infect Dis. 2022;226(10):1809–22.PubMedPubMedCentralCrossRef
37.
Lee CH, Wu MZ, Lui D, Fong C, Ren QW, et al. Prospective associations of circulating thrombospondin-2 level with heart failure hospitalization, left ventricular remodeling and diastolic function in type 2 diabetes. Cardiovasc Diabetol. 2022;21(1):231.PubMedPubMedCentralCrossRef
38.
Wallentin L, Eriksson N, Olszowka M, Grammer TB, Hagström E, et al. Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: a retrospective study. PLoS Med. 2021;18(1):e1003513.PubMedPubMedCentralCrossRef
39.
Herder C, Kannenberg JM, Carstensen-Kirberg M, Strom A, Bonhof GJ, et al. A systemic inflammatory signature reflecting Cross Talk between Innate and adaptive immunity is Associated With Incident Polyneuropathy: KORA F4/FF4 study. Diabetes. 2018;67(11):2434–42.PubMedCrossRef
40.
Lu X, Wang Z, Ye D, Feng Y, Liu M, et al. The role of CXC chemokines in Cardiovascular diseases. Front Pharmacol. 2021;12:765768.PubMedCrossRef
41.
42.
Zhang D, Contu R, Latronico MV, Zhang J, Rizzi R, et al. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J Clin Invest. 2010;120(8):2805–16.PubMedPubMedCentralCrossRef
43.
Pan J, Nilsson J, Engström G, De Marinis Y. Elevated circulating follistatin associates with increased risk of mortality and cardiometabolic disorders. Nutr Metabolism Cardiovasc Dis. 2023.
44.
Goncalves I, Hultman K, Duner P, Edsfeldt A, Hedblad B, et al. High levels of cathepsin D and cystatin B are associated with increased risk of coronary events. Open Heart. 2016;3(1):e000353.PubMedPubMedCentralCrossRef
45.
Gallo S, Sala V, Gatti S, Crepaldi T. Cellular and molecular mechanisms of HGF/Met in the cardiovascular system. Clin Sci (Lond). 2015;129(12):1173–93.PubMedCrossRef
46.
Bielinski SJ, Berardi C, Decker PA, Larson NB, Bell EJ, et al. Hepatocyte growth factor demonstrates racial heterogeneity as a biomarker for coronary heart disease. Heart. 2017;103(15):1185–93.PubMedCrossRef
47.
Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351(25):2599–610.PubMedCrossRef
48.
Cassidy A, Chiuve SE, Manson JE, Rexrode KM, Girman CJ, et al. Potential role for plasma placental growth factor in predicting coronary heart disease risk in women. Arterioscler Thromb Vasc Biol. 2009;29(1):134–9.PubMedCrossRef
49.
Ligthart S, Sedaghat S, Ikram MA, Hofman A, Franco OH, et al. EN-RAGE: a novel inflammatory marker for incident coronary heart disease. Arterioscler Thromb Vasc Biol. 2014;34(12):2695–9.PubMedCrossRef
50.
Durda P, Sabourin J, Lange EM, Nalls MA, Mychaleckyj JC, et al. Plasma levels of Soluble Interleukin-2 receptor alpha: associations with Clinical Cardiovascular events and genome-wide Association scan. Arterioscler Thromb Vasc Biol. 2015;35(10):2246–53.PubMedPubMedCentralCrossRef
51.
Casselbrant A, Fedorowski A, Frantz S, Engstrom G, Wollmer P, et al. Common physiologic and proteomic biomarkers in pulmonary and coronary artery disease. PLoS ONE. 2022;17(3):e0264376.PubMedPubMedCentralCrossRef
52.
Matsumoto S, Kishida K, Shimomura I, Maeda N, Nagaretani H, et al. Increased plasma HB-EGF associated with obesity and coronary artery disease. Biochem Biophys Res Commun. 2002;292(3):781–6.PubMedCrossRef
53.
Jin W, Zhao Y, Yan W, Cao L, Zhang W, et al. Elevated circulating interleukin-27 in patients with coronary artery disease is associated with dendritic cells, oxidized low-density lipoprotein, and severity of coronary artery stenosis. Mediators Inflamm. 2012;2012:506283.
54.
Oh TJ, Ahn CH, Kim BR, Kim KM, Moon JH, et al. Circulating sortilin level as a potential biomarker for coronary atherosclerosis and diabetes mellitus. Cardiovasc Diabetol. 2017;16(1):92.PubMedPubMedCentralCrossRef
55.
Hwang JJ, Yang WS, Chiang FT, Chen MF, Lin HJ, et al. Association of circulating matrix metalloproteinase-1, but not adiponectin, with advanced coronary artery disease. Atherosclerosis. 2009;204(1):293–7.PubMedCrossRef
56.
Carvalho VMF, Oliveira PSS, Albuquerque APB, Rego M, Rosa MMD, et al. Decreased serum levels of Soluble Oncostatin M receptor (sOSMR) and glycoprotein 130 (sgp130) in patients with coronary artery disease. Arq Bras Cardiol. 2023;120(4):e20220326.PubMedPubMedCentralCrossRef
57.
Demyanets S, Speidl WS, Tentzeris I, Jarai R, Katsaros KM, et al. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS ONE. 2014;9(4):e95055.PubMedPubMedCentralCrossRefADS
58.
Lira-Junior R, Bostrom EA, Gustafsson a on behalf of the PAROKRANK steering committee. Periodontitis is associated to increased systemic inflammation in postmyocardial infarction patients. Open Heart. 2021;8(2):e001674.
59.
Ndongo-Thiam N, de Sallmard G, Kastrup J, Miossec P. Levels of soluble osteoclast-associated receptor (sOSCAR) in rheumatoid arthritis: link to disease severity and cardiovascular risk. Ann Rheum Dis. 2014;73(6):1276–7.PubMedCrossRef
60.
Kong P, Cui ZY, Huang XF, Zhang DD, Guo RJ, et al. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022;7(1):131.PubMedPubMedCentralCrossRef
61.
Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91(4):281–91.PubMedCrossRef
62.
McCarthy CP, van Kimmenade RRJ, Gaggin HK, Simon ML, Ibrahim NE, et al. Usefulness of multiple biomarkers for Predicting Incident Major adverse cardiac events in patients who underwent Diagnostic Coronary Angiography (from the Catheter sampled blood archive in Cardiovascular diseases [CASABLANCA] Study). Am J Cardiol. 2017;120(1):25–32.PubMedCrossRef
Metadata
Title
Association of plasma proteomics with incident coronary heart disease in individuals with and without type 2 diabetes: results from the population-based KORA study
Authors
Hong Luo
Marie-Theres Huemer
Agnese Petrera
Stefanie M. Hauck
Wolfgang Rathmann
Christian Herder
Wolfgang Koenig
Annika Hoyer
Annette Peters
Barbara Thorand
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2024
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-024-02143-z

Other articles of this Issue 1/2024

Cardiovascular Diabetology 1/2024 Go to the issue

Research

Effects of the stress hyperglycemia ratio on long-term mortality in patients with triple-vessel disease and acute coronary syndrome

Research

Sex differences in the association between insulin resistance and non-fatal myocardial infarction across glycaemic states

Research

The association between triglyceride-glucose index and the likelihood of cardiovascular disease in the U.S. population of older adults aged ≥ 60 years: a population-based study

Research

Associations between cardiometabolic indices and the risk of diabetic kidney disease in patients with type 2 diabetes

Research

Impact of acute glycemic variability on short-term outcomes in patients with ST-segment elevation myocardial infarction: a multicenter population-based study

Research

Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits